BMS-214662

• Description :

  BMS-214662 is a farnesyl transferase inhibitor. BMS-214662 can effectively block the localization and function of Ras protein in the cell membrane by inhibiting the pro-group modification of Ras protein, thereby exerting anti-tumor activity. BMS-214662 has an IC50 value of 1.3 nM for H-Ras and 8.4 nM for K-Ras. BMS-214662 can be used to study Ras-related tumor diseases[1][2].

• CAS Number :

  [195987-41-8]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319

• Target :

  Farnesyl Transferase; Ras

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/BMS-214662.html

• Purity :

  99.86

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  N#CC1=CC=C(N(CC2=CN=CN2)C[C@@H](CC3=CC=CC=C3)N(S(=O)(C4=CC=CS4)=O)C5)C5=C1

• Molecular Formula :

  C25H23N5O2S2

• Molecular Weight :

  489.61

• Precautions :

  H302, H315, H319

• References & Citations :

  [1]Hunt JT, et al. Discovery of (R) -7-cyano-2,3,4, 5-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3- (phenylmethyl) -4- (2-thienylsulfonyl) -1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem. 2000 Oct 5;43 (20) :3587-95.|[2]Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61 (20) :7507-17.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1